BCL2 and neoplasm: On the other hand, a combination (TZB+ATV) therapy (Fig 3D) can increase the anti-tumor efficacy by decreasing the overall expression levels of IL-6, NFκB (green dashed), and Bcl-2 (red solid), and by increasing the overall BAX levels (blue circle).